# Diabetic Retinopathy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/diabetic-retinopathy

> 2 upcoming FDA catalysts in diabetic Retinopathy: surabgene lomparvovec (ABBV) on June 2028 (primary completion); surabgene lomparvovec (ABBV) on Jun to Sep 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 13, 2026 | [Tarcocimab primary completion](https://sec-api.dev/pdufa/tarcocimab) | KOD | Diabetic Retinopathy | completed | "NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-13 (ACTUAL); Lead Sponsor Kodiak Sciences Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06270836)) |
| June 2028 | [Surabgene lomparvovec primary completion](https://sec-api.dev/pdufa/surabgene-lomparvovec) | ABBV | Diabetic Retinopathy | scheduled | "NCT07592273 (Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07592273)) |
| Jun to Sep 2028 | [Surabgene lomparvovec topline data readout](https://sec-api.dev/pdufa/surabgene-lomparvovec) | ABBV | Diabetic Retinopathy | scheduled | "NCT07592273 (Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07592273)) |

## Drugs

- [Tarcocimab](https://sec-api.dev/pdufa/tarcocimab) (KOD)
- [Surabgene lomparvovec](https://sec-api.dev/pdufa/surabgene-lomparvovec) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/diabetic-retinopathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Diabetic Retinopathy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/diabetic-retinopathy

```bibtex
@misc{secapidev_indications_diabetic_retinopathy_20261116,
  title        = {Diabetic Retinopathy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/diabetic-retinopathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_diabetic_retinopathy_20261116","title":"Diabetic Retinopathy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/diabetic-retinopathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
